Laura Deming: I'm very interested in the tradeoff and relation between investing more in basic science (with the goal of major theoretical breakthroughs) and developing technology and products (which can have immediate impact but perhaps not as important in the long term).
For example,
1. What is the role of the Academia in progress on aging, as opposed to private research groups? In general, how much resources do they have and what are they incentivized to?
2. What are the current bottlenecks in longevity research and tech?
3. How do you view the market and general public view of longevity in the near future?
Rob Wiblin: Are Forum comments fine for submitting questions, or is there another way you'd prefer they be submitted?
Laura Deming: Some question derived from the following cluster:
Liv and Natalie: If you're working with/talking to a potential donor who already has a history of donating heavily to non-EA causes/organizations, how does that change the way you approach your pitch? Do you ever attempt to nudge donors away from organizations they've supported, or is that always a bad idea? (It seems difficult to do this kind of nudge if the donor doesn't initiate it themselves, but nudging successfully could free up millions of dollars in additional funding.)